Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy.
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Demyelination: the role of reactive oxygen and nitrogen species.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Receptos provides update on progress of lead product candidate RPC1063
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Time limited immunomodulatory functions of transplanted neural precursor cells.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
FDA warns about seizures linked to MS drug
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Medicare Part D payments for neurologist-prescribed drugs.

Pages